Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Duolingo Inc (DUOL) Price & Performance

ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.

Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.

Duolingo (DUOL) trades at $132.75, down 3.24% over 24 hours, with a bullish technical outlook from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.66 versus $0.604 expected, driven by 23% daily active user growth. Revenue reached $1.04 billion in 2025, with net income surging to $414 million, though Q3 2026 revenue guidance fell short of expectations, causing recent stock pressure.

The investment outlook is mixed: robust user growth and profitability metrics like a 35.87% net margin support upside, but decelerating bookings growth and margin pressures from AI investments pose risks. Analysts show cautious optimism with a $121 consensus target, highlighting the stock's sensitivity to monetization trends amid competitive threats.